Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

(2018) Wenfeng Fang et al.   LANCET ONCOLOGY

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

(2016) Li Zhang et al.   LANCET

Nasopharyngeal carcinoma

(2016) Melvin L K Chua et al.   LANCET

Multimodality Treatment May Improve the Survival Rate of Patients with Metastatic Nasopharyngeal Carcinoma with Good Performance Status

(2016) Wei Zheng et al.   PLoS One

Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma

(2013) Lei Ma et al.   FEBS Journal

Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations

(2011) Jill Wykosky et al.   Chinese Journal of Cancer

Treatment for metastatic nasopharyngeal carcinoma

(2010) Y. Bensouda et al.   European Annals of Otorhinolaryngology-Head and Neck Diseases

Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma

(2008) Swan Swan Leong et al.   CANCER

Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma

(2008) Yu-Hong Li et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE